Comments on: Patritumab deruxtecan by Daiichi Sankyo for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval /data-insights/patritumab-deruxtecan-daiichi-sankyo-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ The leading site for news and procurement in the pharmaceutical industry Mon, 09 Sep 2024 06:51:41 +0000 hourly 1 https://wordpress.org/?v=6.6.2